Keros Therapeutics (KROS) Receivables - Other (2019 - 2020)

Keros Therapeutics' (KROS) quarterly Receivables - Other came in at $805000.0 in Q1 2020, down 10.56% on a QoQ basis from $900000.0 in Q4 2019.

Keros Therapeutics (KROS) Receivables - Other (2019 - 2020) Analysis & Trends

Keros Therapeutics (KROS) has 2 years of Receivables - Other data on file, last reported at $805000.0 in Q1 2020.

Quarterly Receivables - Other changed N/A year-over-year to $805000.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $805000.0 (changed N/A YoY) and the FY2019 annual result came in at $900000.0, changed N/A from the prior year.
Receivables - Other retreated to $805000.0 in Q1 2020, from $900000.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $900000.0 in Q4 2019 to a low of $805000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.98 Bn	77.99 Bn	3.93 Bn
3	Argenx Se	65.11 Bn	59.92 Bn	1.37 Bn
4	Moderna	55.73 Bn	50.59 Bn	52.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn
9	Royalty Pharma	27.32 Bn	26.49 Bn	-
10	Keros Therapeutics	215.72 Mn	-41.88 Mn	-

Download Data